DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Phase 1

Completed

Conditions: NAFLD
Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease

Interventions: Drug: BMS-986036

First Posted Date: 2018-09-17

Last Posted Date: 2019-10-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT03674476

Locations: 🇨🇿
Pharmaceutical Research Associates CZ, s.r.o, Praha 7, Czechia
🇭🇺
Clinical Research Unit Hungary, Miskolc, Hungary
🇭🇺
PRA Magyarorszag Kft, Budapest, Hungary

and more 1 locations

A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2018-09-13

Last Posted Date: 2022-05-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1132

Registration Number: NCT03670667

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Phase 2

Completed

Conditions: Pan Tumor

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2018-09-12

Last Posted Date: 2024-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 212

Registration Number: NCT03668119

Locations: 🇺🇸
John Wayne Cancer Center, Santa Monica, California, United States
🇦🇷
Local Institution - 0078, Caba, Argentina
🇺🇸
Broome Oncology, Johnson City, New York, United States

and more 57 locations

Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2018-09-10

Last Posted Date: 2022-03-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2052

Registration Number: NCT03663829

A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread

Completed

Conditions: Kidney Cancer
Renal Cell Carcinoma

Interventions: Other: Non-Interventional

First Posted Date: 2018-09-10

Last Posted Date: 2022-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 81

Registration Number: NCT03663946

Locations: 🇯🇵
Local Institution, Tokyo, Japan

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Urinary Bladder Neoplasms
Muscle-Invasive Bladder Cancer

Interventions: Biological: Nivolumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2018-09-07

Last Posted Date: 2024-01-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 861

Registration Number: NCT03661320

Locations: 🇫🇮
Local Institution - 0146, Turku, Finland
🇩🇪
Local Institution - 0013, Herne, Germany
🇧🇪
Local Institution - 0060, Bruxelles, Belgium

and more 168 locations

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Phase 2

Completed

Conditions: Gastric Cancer
Cancer of the Stomach
Esophagogastric Junction

Interventions: Biological: BMS-986213
Biological: Nivolumab
Drug: XELOX
Drug: FOLFOX
Drug: SOX

First Posted Date: 2018-09-07

Last Posted Date: 2025-02-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 274

Registration Number: NCT03662659

Locations: 🇩🇪
Local Institution - 0014, Frankfurt, Germany
🇺🇸
Local Institution - 0040, Los Angeles, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

and more 76 locations

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: BMS-986310
Biological: Nivolumab

First Posted Date: 2018-09-07

Last Posted Date: 2021-11-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 27

Registration Number: NCT03661632

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 2 locations

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: MMF

First Posted Date: 2018-09-06

Last Posted Date: 2018-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT03660436

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma

Withdrawn

Conditions: Multiple Myeloma

Interventions: Other: Non-Interventional

First Posted Date: 2018-09-06

Last Posted Date: 2022-05-27

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03660072

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy